Your browser is no longer supported. Please, upgrade your browser.
ACET [NASD]
Adicet Bio, Inc.
Index- P/E- EPS (ttm)-4.45 Insider Own11.92% Shs Outstand31.82M Perf Week5.70%
Market Cap231.80M Forward P/E- EPS next Y-2.21 Insider Trans-3.14% Shs Float28.05M Perf Month3.54%
Income-55.90M PEG- EPS next Q-0.44 Inst Own66.90% Short Float1.47% Perf Quarter-21.65%
Sales9.30M P/S24.92 EPS this Y70.30% Inst Trans4.45% Short Ratio2.89 Perf Half Y-42.16%
Book/sh7.18 P/B1.06 EPS next Y-10.50% ROA-26.20% Target Price- Perf Year-27.96%
Cash/sh6.84 P/C1.11 EPS next 5Y29.10% ROE-32.30% 52W Range6.25 - 17.80 Perf YTD-45.91%
Dividend- P/FCF- EPS past 5Y- ROI-33.10% 52W High-57.30% Beta2.43
Dividend %- Quick Ratio10.30 Sales past 5Y- Gross Margin- 52W Low21.60% ATR0.44
Employees81 Current Ratio10.30 Sales Q/Q-49.50% Oper. Margin- RSI (14)52.53 Volatility5.70% 5.93%
OptionableYes Debt/Eq0.00 EPS Q/Q88.90% Profit Margin- Rel Volume1.19 Prev Close7.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume142.91K Price7.60
Recom1.40 SMA20-0.14% SMA501.59% SMA200-35.80% Volume170,592 Change4.40%
May-18-21Initiated BTIG Research Buy $34
Apr-23-21Initiated H.C. Wainwright Buy $27
Apr-14-21Initiated Canaccord Genuity Buy $28
Apr-08-21Initiated Guggenheim Buy $22
Nov-04-20Initiated B. Riley Securities Buy $30
Oct-27-20Initiated JMP Securities Mkt Outperform $30
Oct-16-20Initiated Wedbush Outperform $25
Sep-13-21 08:00AM  
08:00AM  
Sep-02-21 04:53PM  
Aug-12-21 04:01PM  
Aug-02-21 07:00AM  
Jul-30-21 10:35AM  
Jul-15-21 07:00AM  
Jun-28-21 07:00AM  
May-18-21 04:10PM  
May-17-21 07:01AM  
Apr-29-21 07:00AM  
Apr-15-21 07:00AM  
Apr-13-21 07:00AM  
Mar-11-21 04:10PM  
Mar-10-21 07:00AM  
Mar-04-21 04:01PM  
Feb-16-21 07:00AM  
Feb-11-21 07:00AM  
Feb-10-21 07:51AM  
Feb-09-21 04:04PM  
Jan-07-21 07:00AM  
Dec-15-20 11:19PM  
Dec-08-20 07:00AM  
Dec-07-20 11:37PM  
Dec-01-20 07:00AM  
Nov-06-20 07:00AM  
Nov-05-20 04:10PM  
Oct-26-20 04:10PM  
Oct-22-20 07:00AM  
Oct-01-20 04:10PM  
Sep-22-20 10:42PM  
Sep-21-20 07:00AM  
Sep-18-20 04:10PM  
Sep-16-20 07:00AM  
Sep-15-20 04:10PM  
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schor ChenPresident & CEOJun 16Sale10.5316,466173,44374,841Jun 21 04:25 PM
Jakobovits AyaDirectorJun 15Sale11.163,84742,919215,883Jun 17 06:08 PM
Galimi FrancescoSVP & Chief Medical OfficerJun 04Option Exercise5.976,98341,6896,983Jun 08 09:35 PM
Schor ChenPresident & CEOJun 03Sale12.0616,466198,49982,325Jun 07 07:12 PM
Jakobovits AyaDirectorMay 20Sale14.231,79225,498217,806May 20 07:28 PM
Schor ChenPresident & CEOMay 19Sale13.4516,466221,43689,809May 21 04:34 PM
Jakobovits AyaDirectorMay 18Sale14.056,20887,249218,699May 20 07:28 PM
Jakobovits AyaDirectorMay 12Sale13.2310,000132,332221,806May 14 04:33 PM
Schor ChenPresident & CEOMay 05Sale14.2216,466234,22297,293May 07 04:02 PM
Schor ChenPresident and CEOApr 20Sale12.0116,466197,676104,777Apr 22 04:34 PM
Schor ChenPresident and CEOApr 06Sale13.0416,466214,700112,261Apr 08 04:37 PM
Schor ChenPresident and CEOMar 16Sale15.3416,466252,558127,229Mar 18 09:55 PM